Non-e of the interaction conditions were significant at the 0.05 level. Tumor Response and Progression-free Survival The objective response rate was higher with nivolumab than with everolimus . Partial responses were observed in 99 patients in the nivolumab group and in 20 individuals in the everolimus group. Total responses were seen in 4 patients in the nivolumab group and in 2 sufferers in the everolimus group. The median time to response was 3.5 months among the 103 patients with a reply in the nivolumab group and 3.7 months among the 22 patients with a response in the everolimus group; the median duration of response was 12.0 months with nivolumab and 12.0 months with everolimus .The interactive computer-vision software employs the webcam on a smartphone or tablet computer to immediately monitor medication adherence in medical trials and ongoing care settings. Clinical trial coordinators and healthcare providers can use the technology to automatically monitor patient medication adherence in real-time. Utilizing their tablets or smartphones, patients are alerted to take their medicine and can activate the system that will confirm their identity, the medication and confirm medicine ingestion. The simple process takes 15 secs to complete. Adherence data are immediately and safely transmitted to a centralized dashboard. Nonadherence events, including skipped doses or incorrect medication ingestion, result in alerts that allow instantly coordinators or providers to intervene, using a variety of integrated communication choices.WORK showcases potential technology and improvements in deep learning software program ‘Through our patent-pending computer vision technology, we're in a position to merely and inexpensively automate the process of watching a patient take their medication – otherwise known as directly observed therapy – and extend this process to a inhabitants level.